SLShuwei Li

Shuwei Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shuwei Li has a total of 304 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers
    Open Access

    Whole-genome sequencing of 490,640 UK Biobank participants

    by The UK Biobank Whole-Genome Sequencing Consortium, Manuscript Writing Group, Keren Carss, Bjarni V. Halldorsson, Liping Hou, Jimmy Liu, Eleanor Wheeler, Yancy Lo, Kousik Kundu, Zhuoyi Huang, et al.

    Whole-genome sequencing provides an unbiased and complete view of the human genome and enables the discovery of genetic variation without the technical limitations of other genotyping technologies. Here we report on whole-genome sequencing of 490,640 UK Biobank participants, building on previous genotyping effort1. This advance deepens our understanding of how genetics associates with disease biology and further enhances the value of this open resource for the study of human biology and health. Coupling this dataset with rich phenotypic data, we surveyed within- and cross-ancestry genomic associations and identified novel genetic and clinical insights. Although most associations with disease traits were primarily observed in individuals of European ancestries, strong or novel signals were also identified in individuals of African and Asian ancestries. With the improved ability to accurately genotype structural variants and exonic variation in both coding and UTR sequences, we strengthened and revealed novel insights relative to whole-exome sequencing2,3 analyses. This dataset, representing a large collection of whole-genome sequencing data that is available to the UK Biobank research community, will enable advances of our understanding of the human genome, facilitate the discovery of diagnostics and therapeutics with higher efficacy and improved safety profile, and enable precision medicine strategies with the potential to improve global health.


  • W40. TOWARD PRECISION PSYCHIATRY: MACHINE LEARNING-DRIVEN PATIENT STRATIFICATION OF MAJOR DEPRESSIVE DISORDER REVEALS BIOLOGICALLY DISTINCT SUBTYPES

    by Dongnhu Truong, Ekaterina Khramtsova, Parth Patel, Qingqin Li, Guang Chen, Srinivasan Vairavan, Christopher Whelan, Brice Sarver, Gunaretnam Rajagopal, Tommaso Mansi, et al.

  • Open Access

    Characterization of APOE Christchurch carriers in 455,306 UK Biobank participants

    by Karen Y. He, Ekaterina A. Khramtsova, Alfredo Cabrera-Socorro, Yanfei Zhang, Shuwei Li, Brice A. J. Sarver, Bart Smets, Qingqin S. Li, Louis De Muynck, Antonio R. Parrado, et al.

    Importance: A few case studies have reported the APOE Christchurch (APOECh) variant to confer protective effects for Alzheimer’s disease (AD) and a higher risk of premature cardiovascular disease (CVD). However, these studies primarily focused on a single individual or siblings from the same family. Objective: We sought to characterize the clinical characteristics of individuals with APOECh variation in 455,306 participants of the UK Biobank (UKB) to determine whether it is associated with AD protection or cardiovascular risk. Design, Setting, and Participants: A total of 37 individuals were identified as heterozygous carriers of APOECh in UKB sequencing data as of March 2022, resulting in allele frequency consistent with gnomAD (4.06×10 −5 ). We limited our study to 36 European carriers and generated a noncarrier cohort matched on age, sex, and ancestry. Case-control analyses were performed to evaluate the frequency of 11 binary traits and differences in distributions of 80 quantitative traits and 10 polygenic risk scores (PRS) for lipid traits, CVD, and neurodegenerative diseases. Main Outcomes and Measures: We compared the frequencies of binary traits (binomial distribution probability) and distributions of quantitative traits and PRS (Kolmogorov-Smirnov test). Results: All 37 carriers are free of AD and only 4 have a parental history of AD. There are 22 out of 37 carriers with > 1 cardiovascular (CV) condition in clinical and/or self-reported data, two of whom passed away due to heart disease. However, frequency of CVD, dyslipidemia, and hypertension is not enriched in carriers compared with matched non-carriers. Additionally, apolipoprotein B (apoB) is significantly lower in APOECh carriers before (p=0.004) and after statin adjustment (p=0.04). Comparisons of PRS show that carriers and non-carriers have a similar genetic burden of developing dyslipidemia and CVD, but carriers have lower PRS-based AD risk (p=0.02). Conclusions and Relevance: This study demonstrates that APOECh carriers may have lower levels of apoB and a lower risk of AD. Cohorts with enriched cases are needed to further investigate whether the protective effect is linked to APOE genotypes or other factors. Key Points: Question: How does APOE Christchurch (APOECh) variant influence risk of Alzheimer’s disease (AD), cardiovascular disease, and dyslipidemia? Findings: APOECh carriers do not have an elevated risk of dyslipidemia. However, carriers have lower levels of apolipoprotein B (apoB). Comparing polygenic risk scores of carriers vs. noncarriers of APOECh shows carriers are at a lower risk of developing AD before but not after adjusting for multiple comparisons. Meaning: Carriers of APOECh may have a lower risk of developing AD due to lower apoB; however, further epidemiological and model organism studies are needed to validate these observations from the current study.


  • Open Access

    Prevalence of Germline Pathogenic and Likely Pathogenic Variants in Patients With Second Breast Cancers

    by Katharine A Yao K, Jacob Clifford, Shuwei Li, Holly LaDuca, Peter Hulick, Stephanie Gutierrez, Mary Helen Black

    Few studies have examined gene-specific associations with contralateral and/or second breast cancer (SBC). The frequency of pathogenic and likely pathogenic (P/LP) variants in clinically actionable genes (BRCA1, BRCA2, PTEN, TP53, CHEK2, CDH1, ATM, PALB2, NBN, and NF1) was compared between women with a primary breast cancer (PBC) and SBC who underwent multigene panel testing at a single diagnostic testing laboratory. Race- and ethnicity-specific logistic regression burden tests adjusted for age at diagnosis of first breast cancer, histology, presence of first- or second-degree relatives with breast cancer, and prior testing for BRCA1/2 genes were used to test for associations with SBC. All statistical tests were 2-sided. The study was comprised of 75 550 women with PBC and 7728 with SBC. Median time between breast cancers for SBC was 11 (interquartile range = 6–17) years. Restricting to women tested for all actionable genes (n = 60 310), there were 4231 (7.8%) carriers of P/LP variants in actionable genes among the controls (PBC) compared with 652 (11.1%) women with SBC (P< .001). Among Caucasians, exclusive of Ashkenazi Jewish women, those carrying a P/LP variant in a clinically actionable gene were 1.44 (95% confidence interval [CI] = 1.30 to 1.60) times as likely to have SBC than noncarriers, after accounting for potential confounders. Among African American and Hispanic women, a P/LP variant in a clinically actionable gene was 1.88 (95% CI = 1.36 to 2.56) and 1.66 (9% CI = 1.02 to 2.58) times as likely to be associated with SBC, respectively (P < .001 and P = .03). Women with P/LP variants in breast cancer predisposition genes are more likely to have SBC than noncarriers. Prospective studies are needed confirm these findings.


  • Open Access

    Validation of a prostate cancer polygenic risk score

    by Mary H. Black, Shuwei Li, Holly LaDuca, Min‐Tzu Lo, Jefferey Chen, Robert Hoiness, Stephanie Gutierrez, Brigette Tippin‐Davis, Hsiao‐Mei Lu, Marta Gielzak, et al.

    Background: Genome‐wide association studies have identified over 100 single‐nucleotide polymorphisms (SNPs) associated with prostate cancer (PrCa), and polygenic risk scores (PRS) based on their combined genotypes have been developed for risk stratification. We aimed to assess the contribution of PRS to PrCa risk in a large multisite study.Methods: The sample included 1972 PrCa cases and 1919 unaffected controls. Next‐generation sequencing was used to assess pathogenic variants in 14 PrCa‐susceptibility genes and 72 validated PrCa‐associated SNPs. We constructed a population‐standardized PRS and tested its association with PrCa using logistic regression adjusted for age and family history of PrCa.Results: The mean age of PrCa cases at diagnosis and age of controls at testing/last clinic visit was 59.5 ± 7.2 and 57.2 ± 13.0 years, respectively. Among 1740 cases with pathology data, 57.4% had Gleason score ≤ 6, while 42.6% had Gleason score ≥ 8. In addition, 39.6% cases and 20.1% controls had a family history of PrCa. The PRS was significantly higher in cases than controls (mean ± SD: 1.42 ± 1.11 vs 1.02 ± 0.76; P < .0001). Compared with men in the 1st quartile of age‐adjusted PRS, those in the 2nd, 3rd, and 4th quartile were 1.58 (95% confidence interval [CI]: 1.31‐1.90), 2.36 (95% CI: 1.96‐2.84), and 3.98 (95% CI: 3.29‐4.82) times as likely to have PrCa (all P < .0001). Adjustment for family history yielded similar results. PRS predictive performance was consistent with prior literature (area under the receiver operating curve = 0.64; 95% CI: 0.62‐0.66).Conclusions: These data suggest that a 72‐SNP PRS is predictive of PrCa, supporting its potential use in clinical risk assessment.


  • Rare Germline Pathogenic Mutations of DNA Repair Genes Are Most Strongly Associated with Grade Group 5 Prostate Cancer

    by Yishuo Wu, Hongjie Yu, Shuwei Li, Kathleen Wiley, S. Lilly Zheng, Holly LaDuca, Marta Gielzak, Rong Na, Brice A.J. Sarver, Brian T. Helfand, et al.


  • Tumour characteristics provide evidence for germline mismatch repair missense variant pathogenicity

    by Shuwei Li, Dajun Qian, Bryony A Thompson, Stephanie Gutierrez, Sitao Wu, Tina Pesaran, Holly LaDuca, Hsiao-Mei Lu, Elizabeth C Chao, Mary Helen Black

    Background: Pathogenic variants in mismatch repair (MMR) genes (MLH1, MSH2, MSH6 and PMS2) increase risk for Lynch syndrome and related cancers. We quantified tumour characteristics to assess variant pathogenicity for germline MMR genes. Methods: Among 4740 patients with cancer with microsatellite instability (MSI) and immunohistochemical (IHC) results, we tested MMR pathogenic variant association with MSI/IHC status, and estimated likelihood ratios which we used to compute a tumour characteristic likelihood ratio (TCLR) for each variant. Predictive performance of TCLR in combination with in silico predictors, and a multifactorial variant prediction (MVP) model that included allele frequency, co-occurrence, co-segregation, and clinical and family history information was assessed. Results: Compared with non-carriers, carriers of germline pathogenic/likely pathogenic (P/LP) variants were more likely to have abnormal MSI/IHC status (p76.7% variants. Adding TCLR as quantitative evidence in an MVP model (MVP +TCLR Pred) increased the proportion of accurately classified variants from 88.0% (MVP alone) to 98.0% and generated optimal performance statistics among all models tested. Importantly, MVP +TCLR Pred resulted in the high yield of predicted classifications for missense variants of unknown significance (VUS); among 193 VUS, 62.7% were predicted as P/PL or benign/likely benign (B/LB) when assessed according to American College of Medical Genetics and Genomics/Association for Molecular Pathology guidelines. Conclusion: Our study demonstrates that when used separately or in conjunction with other evidence, tumour characteristics provide evidence for germline MMR missense variant assessment, which may have important implications for genetic testing and clinical management.


  • Open Access

    Clinical features and cancer risk in families with pathogenicCDH1variants irrespective of clinical criteria

    by Rosa M Xicola, Shuwei Li, Nicolette Rodriguez, Patrick Reinecke, Rachid Karam, Virginia Speare, Mary Helen Black, Holly LaDuca, Xavier Llor

    Background: The clinical phenotype ofCDH1pathogenic variant carriers has mostly been studied in families that fulfil criteria of hereditary diffuse gastric cancer (HDGC). We aimed at determining cancer phenotype and cancer risk estimation among families withCDH1pathogenic variants not selected by HDGC clinical criteria.Methods: Patients were all consecutively identifiedCDH1pathogenic variant carriers from a clinical laboratory tested with multigene panel testing and from an academic cancer genetics programme. Clinical and demographic features, cancer phenotypes and genotype–phenotype correlations were determined amongCDH1families. Age-specific cumulative cancer risks (penetrance) were calculated based on 38 families with available pedigrees.Results: Within the 113CDH1pathogenic variant probands and 476 relatives, 113 had gastric cancer, 177 breast cancer and 196 other cancers. Mean age at diagnosis was 47 for gastric and 54 for breast cancer. Forty-six per cent fulfilled criteria of HDGC. While 36% of families had both gastric and breast cancers, 36% had breast but no gastric cancers and 16% had gastric but not breast cancers. Cumulative risk of cancer by age 80 was 37.2% for gastric and 42.9% for breast cancer.Conclusion: In unselectedCDH1pathogenic variant carrier families, gastric cancer risks were lower and age at diagnosis higher than previously reported in families pre-selected for HDGC criteria. A substantial proportion of families did not present with any gastric cancers and their cancers were limited to breast. Thus, clinical criteria forCDH1testing should be widened, including breast cancer families only, and a consideration for delayed prophylactic gastrectomy/surveillance should be evaluated.


  • Open Access

    A Bayesian framework for efficient and accurate variant prediction

    by Dajun Qian, Shuwei Li, Yuan Tian, Jacob W Clifford, Brice A J Sarver, Tina Pesaran, Chia-Ling Gau, Aaron M Elliott, Hsiao-Mei Lu, Mary Helen Black

    There is a growing need to develop variant prediction tools capable of assessing a wide spectrum of evidence. We present a Bayesian framework that involves aggregating pathogenicity data across multiple in silico scores on a gene-by-gene basis and multiple evidence statistics in both quantitative and qualitative forms, and performs 5-tiered variant classification based on the resulting probability credible interval. When evaluated in 1,161 missense variants, our gene-specific in silico model-based meta-predictor yielded an area under the curve (AUC) of 96.0% and outperformed all other in silico predictors. Multifactorial model analysis incorporating all available evidence yielded 99.7% AUC, with 22.8% predicted as variants of uncertain significance (VUS). Use of only 3 auto-computed evidence statistics yielded 98.6% AUC with 56.0% predicted as VUS, which represented sufficient accuracy to rapidly assign a significant portion of VUS to clinically meaningful classifications. Collectively, our findings support the use of this framework to conduct large-scale variant prioritization using in silico predictors followed by variant prediction and classification with a high degree of predictive accuracy.


  • Clinical germline diagnostic exome sequencing for hereditary cancer: Findings within novel candidate genes are prevalent

    by Zöe Powis, Carin R. Espenschied, Holly LaDuca, Kelly D. Hagman, Tripti Paudyal, Shuwei Li, Hiroto Inaba, Ann Mauer, Katherine L. Nathanson, James Knost, et al.